A m⁶Avalue predictive of prostate cancer stemness, tumor immune landscape and immunotherapy response.

ABSTRACT: The molecular mechanisms underpinning prostate cancer (PCa) progression are incompletely understood, and precise stratification of aggressive primary PCa (pri-PCa) from indolent ones poses a major clinical challenge. Here, we comprehensively dissect, genomically and transcriptomically, the m⁶A (N ⁶-methyladenosine) pathway as a whole in PCa. Expression, but not the genomic alteration, repertoire of the full set of 24 m⁶A regulators at the population level successfully stratifies pri-PCa into three m⁶A clusters with distinct molecular and clinical features. These three m⁶A modification patterns closely correlate with androgen receptor signaling, stemness, proliferation and tumor immunogenicity of cancer cells, and stroma activity

SUBMITTER: Zou C 

PROVIDER: S-EPMC8953419 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature